Immuron (ASX:IMC) recorded a 13% quarterly increase in the global sales of its immune supplement, Travelan, in the September quarter, according to a Tuesday filing with the Australian bourse.
Sales of Travelan in Australia increased 3% to AU$1 million in the September quarter from AU$983,000 in the three months to June. North American sales climbed 48% to AU$456,000 from AU$309,000 in the June quarter.
The biopharmaceutical company's shares were up nearly 4% in recent Tuesday trade.
Price (AUD): $0.09, Change: $+0.003, Percent Change: +3.66%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。